Benzinga | Nov 23, 2020 08:08AM EST

Halozyme Therapeutics Raises FY2020 Sales Guidance from $250.00M-260.00M to $265.00M-275.00M

Halozyme Therapeutics (NASDAQ:HALO) raises FY2020 sales outlook from $250.00 million-260.00 million to $265.00 million-275.00 million.